While dabigatran was generally prescribed appropriately for nonvalvular atrial fibrillation in patients without renal impairment, there is a need for improved documentation of risks and management of concurrent interacting medications.
No takes yet. Share an insight, caveat, or question.
Dabigatran met hospital restrictions in 84% of inpatients; leaves open need for improved valvular screening, interaction checks, and risk documentation before broader adoption.
Carter et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: